152 related articles for article (PubMed ID: 18161051)
1. Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.
Umemura A; Itoh Y; Itoh K; Yamaguchi K; Nakajima T; Higashitsuji H; Onoue H; Fukumoto M; Okanoue T; Fujita J
Hepatology; 2008 Feb; 47(2):493-502. PubMed ID: 18161051
[TBL] [Abstract][Full Text] [Related]
2. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.
Sun W; Ding J; Wu K; Ning BF; Wen W; Sun HY; Han T; Huang L; Dong LW; Yang W; Deng X; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2011 Oct; 54(4):1259-72. PubMed ID: 21735473
[TBL] [Abstract][Full Text] [Related]
3. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas.
Higashitsuji H; Itoh K; Nagao T; Dawson S; Nonoguchi K; Kido T; Mayer RJ; Arii S; Fujita J
Nat Med; 2000 Jan; 6(1):96-9. PubMed ID: 10613832
[TBL] [Abstract][Full Text] [Related]
4. Expression of p28GANK and its correlation with RB in human hepatocellular carcinoma.
Tan L; Fu XY; Liu SQ; Li HH; Hong Y; Wu MC; Wang HY
Liver Int; 2005 Jun; 25(3):667-76. PubMed ID: 15910504
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
6. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
7. Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance.
Jing H; Zhang G; Meng L; Meng Q; Mo H; Tai Y
Sci Rep; 2014 Jul; 4():5503. PubMed ID: 24999092
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance.
Fu XY; Wang HY; Tan L; Liu SQ; Cao HF; Wu MC
World J Gastroenterol; 2002 Aug; 8(4):638-43. PubMed ID: 12174370
[TBL] [Abstract][Full Text] [Related]
9. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.
Su B; Luo T; Zhu J; Fu J; Zhao X; Chen L; Zhang H; Ren Y; Yu L; Yang X; Wu M; Feng G; Li S; Chen Y; Wang H
Hepatology; 2015 Feb; 61(2):585-97. PubMed ID: 25294684
[TBL] [Abstract][Full Text] [Related]
11. Gankyrin promotes the proliferation of human pancreatic cancer.
Meng Y; He L; Guo X; Tang S; Zhao X; Du R; Jin J; Bi Q; Li H; Nie Y; Liu J; Fan D
Cancer Lett; 2010 Nov; 297(1):9-17. PubMed ID: 20483533
[TBL] [Abstract][Full Text] [Related]
12. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma.
Cheung ST; Wong SY; Leung KL; Chen X; So S; Ng IO; Fan ST
Clin Cancer Res; 2004 Nov; 10(22):7629-36. PubMed ID: 15569995
[TBL] [Abstract][Full Text] [Related]
13. Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation.
Huang SJ; Cheng CL; Chen JR; Gong HY; Liu W; Wu JL
Biochem Biophys Res Commun; 2017 Aug; 490(3):1052-1058. PubMed ID: 28668389
[TBL] [Abstract][Full Text] [Related]
14. Gankyrin, the 26 S proteasome, the cell cycle and cancer.
Mayer RJ; Fujita J
Biochem Soc Trans; 2006 Nov; 34(Pt 5):746-8. PubMed ID: 17052188
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
[TBL] [Abstract][Full Text] [Related]
16. Gankyrin: a new oncoprotein and regulator of pRb and p53.
Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
[TBL] [Abstract][Full Text] [Related]
17. Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression.
Kim YH; Kim JH; Choi YW; Lim SK; Yim H; Kang SY; Chung YS; Lee GY; Park TJ
Exp Mol Pathol; 2013 Apr; 94(2):360-5. PubMed ID: 23276718
[TBL] [Abstract][Full Text] [Related]
18. IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways.
Yumoto E; Nakatsukasa H; Hanafusa T; Yumoto Y; Nouso K; Matsumoto E; Onishi T; Takuma Y; Tanaka H; Fujikawa T; Suzuki M; Uemura M; Shiratori Y
Int J Oncol; 2005 Nov; 27(5):1223-30. PubMed ID: 16211216
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
20. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
Liu R; Li Y; Tian L; Shi H; Wang J; Liang Y; Sun B; Wang S; Zhou M; Wu L; Nie J; Lin B; Tang S; Zhang Y; Wang G; Zhang C; Han J; Xu B; Liu L; Gong K; Zheng T
Cancer Lett; 2019 Feb; 443():34-46. PubMed ID: 30503555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
